Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Savara IncSVRA · Entity 4900 | Chief Medical Officer | December 04, 2025 | December 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Savara Inc
Report date December 04, 2025 · Filed December 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 168,008 |
Reported balance
After 2025-12-04 transaction · row 1
1 source rowRow 1 · 2025-12-04 · Tax withholding · Disposed 21,992 · Balance 168,008 F1: Represents shares withheld by the Issuer in connection with the reporting person's net share settlement to satisfy tax liability based upon the vesting of previously awarded restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer in connection with the reporting person's net share settlement to satisfy tax liability based upon the vesting of previously awarded restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2025 Filed Dec 4, 2025 23:57 UTC | Savara Inc SVRA · Entity 4900 | Tax withholdingCommon Stock | 21,992 | $6.37 | $140,089.04 |
DisclosureSEC source: 0001193125-25-308325 · ownership.xml · nonDerivative · entry 1 Wasfi Yasmine · CIK 0002092127 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,008 F1 · shares: Represents shares withheld by the Issuer in connection with the reporting person's net share settlement to satisfy tax liability based upon the vesting of previously awarded restricted stock units. Read SEC document |
| October 20, 2025 Filed Oct 23, 2025 00:47 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0002092127-25-000004 · ownership.xml · derivative · entry 2 Wasfi Yasmine · CIK 0002092127 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2035-10-20 F2 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of October 17, 2025, subject to the reporting person's continued service with the Issuer. Read SEC document |
| October 20, 2025 Filed Oct 23, 2025 00:47 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002092127-25-000004 · ownership.xml · nonDerivative · entry 1 Wasfi Yasmine · CIK 0002092127 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 F1 · shares: Represents restricted stock units ("RSUs") that vest in full on October 17, 2027, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.